Kevin Drew, MD
Pain Medicine · Mishawaka, INNPI 1275538373
Payments from drug & device makers
Across 431 payments — averaging $29.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Nevro Corp.$2K
- Collegium Pharmaceutical, Inc.$891
- Medtronic$562
- Si-bone, Inc.$373
- Radius Health, Inc.$253
- plus $2K from 33 others
What the payments were for
- Food & beverage$12,600100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 124 | $6,401 |
| Nevro Corp. | 106 | $2,041 |
| Collegium Pharmaceutical, Inc. | 60 | $891 |
| Medtronic | 12 | $562 |
| Si-bone, Inc. | 7 | $373 |
| Radius Health, Inc. | 11 | $253 |
| Amgen | 11 | $200 |
| Pfizer | 9 | $154 |
| Biodelivery Sciences International, Inc. | 10 | $152 |
| Boston Scientific | 6 | $141 |
| GSK | 7 | $140 |
| Pacira Therapeutics, Inc. | 1 | $106 |
| AbbVie | 6 | $101 |
| GRT US Holding, Inc. | 5 | $100 |
| Vertex | 4 | $82 |
| Almatica Pharma LLC | 4 | $77 |
| E.r. Squibb & Sons, L.L.C. | 4 | $74 |
| Supernus Pharmaceuticals, Inc. | 5 | $67 |
| Spinal Simplicity, LLC | 2 | $65 |
| UCB, Inc. | 3 | $65 |
| Eisai Inc. | 3 | $62 |
| Fidia Pharma USA Inc. | 5 | $54 |
| Vertical Pharmaceuticals, LLC | 3 | $45 |
| Redhill Biopharma Inc. | 2 | $42 |
| Assertio Therapeutics, Inc. | 2 | $42 |
| Tersera Therapeutics LLC | 2 | $38 |
| Scilex Pharmaceuticals Inc. | 2 | $36 |
| Orexo US, Inc. | 2 | $33 |
| Nalu Medical, Inc. | 2 | $30 |
| Stryker | 1 | $27 |
| Daiichi Sankyo Inc. | 2 | $26 |
| Averitas Pharma Inc. | 1 | $23 |
| Globus Medical | 1 | $20 |
| Tonix Medicines, Inc. | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$1,998
- Senza Spinal Cord Stimulation System$363
- INTELLIS ADAPTIVESTIM$205
- Omnia$125
- Tymlos$125
- ETERNA$123
- Proclaim IPG$111
- Zilretta$106
- Proclaim Family of SCS IPGs$106
- iFuse Implant$100
How this compares
$12,600 in reported general payments places this provider in the 80th percentile of 128 pain medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fentanyl | 500 | $72,659 |
| BelbucaBuprenorphine Hcl | 70 | $67,622 |
| OxycontinOxycodone Hcl | 61 | $55,612 |
| Nucynta ErTapentadol Hcl | 19 | $39,256 |
| Xtampza ErOxycodone Myristate | 46 | $37,412 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,393 | $35,392 |
| NucyntaTapentadol Hcl | 20 | $29,418 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 838 | $25,516 |
| Morphine Sulfate ErMorphine Sulfate | 604 | $23,672 |
| Gabapentin | 1,057 | $22,837 |
| Pregabalin | 488 | $17,760 |
| Oxymorphone Hcl ErOxymorphone Hcl | 13 | $16,731 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 87 | $12,412 |
| Buprenorphine | 27 | $12,235 |
| Oxycodone Hcl | 386 | $10,632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er, Xtampza Er, Nucynta | $891 | $173,708155 claims |
| Hikma Pharmaceuticals USABuprenorphine-Naloxone, Buprenorphine, Buprenorphine Hcl, Morphine Sulfate | $13 | $32,452272 claims |
| Orexo US, Inc.Zubsolv | $33 | $9,94513 claims |
| PfizerLyrica | $154 | $6,46112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 128 pain medicine providers in Indiana.
Other pain medicine in Mishawaka
- Abhishek DasMishawaka$186K
- Meredith LanghorstFishers$1.5M
- Derron WilsonCarmel$1.3M
- Jonathan GentileCarmel$1.1M
- Kevin MacadaegCarmel$866K
- Robert FunkCarmel$417K
- Andrew TrobridgeMuncie$266K
- Rajiv TewariFishers$140K
- John SwoffordIndianapolis$127K
- Neal ColemanMuncie$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.